相关实验视频

Updated: Jun 15, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

由BRAF诱导的EHF表达影响了侵袭性乳头甲状腺癌中的TERT

Yiyi Xu¹, Jiwei Gao^1,2, Na Wang³

¹Department of Oncology-Pathology, Karolinska Institutet, Stockholm SE-171 64, Sweden.

The Journal of clinical endocrinology and metabolism

|August 25, 2024

概括

通过增加TERT表达,ETS转录因子EHF恶化了皮肤状甲状腺癌 (PTC) 的预后,特别是当BRAFV600E和TERT促进因子突变存在时. 这一发现为PTC提供了新的治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一种遗传学.

背景情况:

乳头甲状腺癌 (PTC) 的预后受到 BRAFV600E 和 TERT 促成因子突变的协同影响.
这种相互作用被认为涉及MAPK激活,导致ETS转录因子上调,以突变的TERT促进体为目标.

研究的目的:

研究ETS因子在PTC中的作用,重点关注它们与临床特征,BRAFV600E和TERT促进子突变的关系.
阐明ETS因素EHF在PTC进展和TERT监管中的具体参与.

主要方法:

对癌症基因组图谱 (TCGA) PTC队列 (n=399) 和局部队列 (n=93) 中28个ETS因子的转录组数据分析.
在体外实验,包括过度表达和敲击研究,以评估EHF在BRAFV600E和TERT表达中的调节作用.
染色体免疫沉 (ChIP) 和定量PCR (qPCR) 用于评估EHF与TERT促进体的结合.

主要成果:

在两个队列中,EHF被确定为与不良临床特征,BRAFV600E和TERT促进体突变/表达相关的关键ETS因子.
高EHF表达与BRAFV600E突变PTC中较短的无病生存时间相关.
同时出现的BRAFV600E,TERT促进子突变和高EHF表达导致了最差的预后.
在具有同时BRAFV600E和TERT促进子突变的细胞中,EHF过度表达增加了TERT表达; BRAF抑制减少了EHF和TERT.
奇普-qPCR建议EHF与突变的TERT促进体结合.

结论:

ETS转录因子EHF与PTC的预后不佳有关.
BRAF-V600E可能对EHF进行升级调节,从而在TERT促进剂突变的PTC细胞中增强TERT表达.
在PTC中,EHF代表了一个潜在的治疗标,特别是在具有特定遗传改变的瘤中.

关键词:

这就是BRAFV600E.欧洲国家庭基金 (EHF)在 TERT 促销者突变中.预后预后预后甲状腺癌是甲状腺癌.

更多相关视频

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...